Cargando…
Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D)
Type 2 diabetes (T2D) imposes a substantial disease burden, predominantly from cardiovascular disease (CVD), which accounts for >50% of deaths in this population and leads to a 12-year reduction in the life expectancy of a 60-year-old male patient with T2D and CVD compared with the general popula...
Autores principales: | Schernthaner, Guntram, Khunti, Kamlesh, Lotan, Chaim, Burnier, Michel, Drexel, Heinz, Prázný, Martin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5733371/ https://www.ncbi.nlm.nih.gov/pubmed/29276388 http://dx.doi.org/10.2147/TCRM.S144362 |
Ejemplares similares
-
Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes
por: Schernthaner, Guntram, et al.
Publicado: (2017) -
The management of type 2 diabetes before, during and after Covid-19 infection: what is the evidence?
por: Czupryniak, Leszek, et al.
Publicado: (2021) -
Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial
por: Inzucchi, Silvio E, et al.
Publicado: (2020) -
Hypoglycemia and Cardiovascular Risks
por: Frier, Brian M., et al.
Publicado: (2011) -
Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG)
por: Schernthaner, Guntram, et al.
Publicado: (2017)